Getting Started

Interested in becoming a participating dementia site or imaging facility?

Thank you for your interest in participating in the New Imaging Dementia—Evidence for Amyloid Scanning (New IDEAS) Study. 

New IDEAS Study leadership commends the participating dementia practices and PET imaging facilities for their continued enthusiasm and commitment to the New IDEAS Study since the first participant was registered in December 2020. After careful consideration of numerous factors and evaluation of the risk-benefit tradeoff for patients, Study leadership decided to end Study accrual on Friday, March 1, 2024 at 11:59pm EST.

Therefore, the Study is no longer activating new dementia practices or imaging facilities for participation in New IDEAS. Please review the study's Recent Study Updates page for more information.

FAQ

Dementia practices and PET facility locations will be approved to participate on a rolling basis. The study team plans to have participating practices and facilities across the United States. Imaging facilities will need to be accessible to patients seeing the referring dementia experts and have access to one of the FDA-approved amyloid imaging agents.

The study plans to cap dementia practice participation at 350 locations. Once sites are selected, they will be listed on the New IDEAS study website. A committee led by the American College of Radiology® is responsible for site selection and will make final decisions based on feasibility questionnaire submissions.


The New IDEAS study is currently reaching out to dementia specialists in areas identified by our community engagement and recruitment team. If you have not been contacted yet and would like to be considered for inclusion in the study, please send an email to newideas@acr.org.

Participation in New IDEAS requires the submission of a site feasibility questionnaire and subsequent approval by the study. Information about the New IDEAS study will also be disseminated via professional organizations dedicated to neurology, psychiatry, geriatrics, nuclear medicine and radiology.

Access the feasibility questionnaire for referring dementia sites.

The New IDEAS study is currently reaching out to dementia specialists in areas identified by our community engagement and recruitment team. Those practices are asked to identify which imaging facility they would plan on referring their patients to. The study team will reach out to the imaging facilities that are identified. If you have not been contacted by the study and would like to be considered as a participating facility, please send an email to newideas@acr.org.

Participation in New IDEAS requires the submission of a site feasibility questionnaire and subsequent approval by the study. Information about the New IDEAS study will also be disseminated via professional organizations dedicated to neurology, psychiatry, geriatrics, nuclear medicine and radiology.

Access the feasibility questionnaire for imaging facilities.

The feasibility questionnaire is available to complete and submit at any time. In general, the study will respond to the applicant within a month of submission. The applicant is not permitted to continue with the next step of site startup before receiving approval from the study team.
You will need to register each component separately. You will also need to complete the feasibility questionnaire for each component. Individual employees can be registered with multiple user roles for both the referring physician site and the PET facility, using the same ACR account.

No. Referring physician practices are required to apply for IRB approval via the central IRB (Advarra). PET facilities are NOT considered “engaged in research” and do not need to apply for IRB approval.

Please refer to the Institutional Review Board page of this website for instructions on how to obtain IRB approval. 

Site agreements from either the PET facility or the referring physician practice should be scanned and emailed to newideas-contracts@acr.org. The agreements will be reviewed and countersigned. The fully executed agreement will be returned to the email address that submitted it. An MS Word version may be requested from the same email address.

Load More